Clarinex Sales

Posted by Administrator on February 24th, 2006 — in Clarinex News

NEW YORK (AFX) — Schering-Plough Corp. said Monday it swung to a profit, helped by sales of Remicade, Peg-Intron, Nasonex and Temodar, though it fell shy of analysts’ expectations.
Shares closed down 2.5% at $19.57, after hitting a session low of $19.50 earlier in the day.
Schering-Plough posted a fourth-quarter profit of $104 million, or 7 cents […]

FDA OKs Clarinex-D 12 Hour

Posted by Administrator on February 13th, 2006 — in Clarinex News

(WebMD) A newer version of the prescription allergy medicine Clarinex has been approved by the FDA to treat nasal and non-nasal symptoms of seasonal allergies including nasal congestion in adults and children over age 12.
Researchers say the new Clarinex-D 12 Hour should be available in time for the spring allergy season.
Clarinex (desloratadine) is […]

FDA Approves CLARINEX-D(R) 12 HOUR (desloratadine 2.5mg/pseudoephedrine 120mg) Tablet Prescription Antihistamine With Decongestant

Posted by Administrator on February 13th, 2006 — in Clarinex News

Schering-Plough Corporation (NYSE: SGP) today announced that the U.S. Food and Drug Administration (FDA) has approved CLARINEX-D® 12 HOUR (desloratadine 2.5 mg and pseudoephedrine sulfate, USP 120 mg) Extended Release Tablets for the relief of nasal and non-nasal symptoms of seasonal allergic rhinitis (outdoor allergies), including nasal congestion, in patients 12 years of age and […]

FDA OKs Clarinex-D 12 Hour

Posted by Administrator on February 13th, 2006 — in Clarinex News

About 36 million people in the US are affected by seasonal allergies. Symptoms include runny nose, sneezing, nasal congestion, and itchy, watery eyes.
A newer version of the prescription allergy medicine Clarinex has been approved by the FDA to treat nasal and non-nasal symptoms of seasonal allergies including nasal congestion in adults and children over age […]

.D.A. Reviews Nonprescription Clarinex

Posted by Administrator on February 2nd, 2006 — in Clarinex News

Efforts by the Schering-Plough Corporation to introduce a nonprescription Claritin, its best-selling allergy drug, may be delayed while the Food and Drug Administration reviews reports of birth defects in babies born to Swedish women who took the drug, the agency said.
The European Agency for the Evaluation of Medicinal Products is investigating reports that Claritin […]

Clarinex / Desloratadine Overview

Posted by Administrator on February 2nd, 2006 — in Clarinex News

Clarinex, also known as desloratadine, is an antihistamine used to treat symptoms of seasonal allergic rhinitis (”hay fever”), including sneezing, runny nose and red, itchy, tearing eyes, in patients 12 years of age and older. Also used to treat hives, Clarinex works by blocking histamine, a substance in the body that causes allergic symptoms. Clarinex […]

FDA approves Clarinex re-formulation

Posted by Administrator on February 2nd, 2006 — in Clarinex News

Schering-Plough has received approval from US regulators to market a re-formulated version of the allergy medicine Clarinex. The reformulated tablets, known as Reditabs, dissolve in the mouth without water.
AdvertisementAccording to the company, this new formulation will be in pharmacies across the US in September 2005, and will be available in both a 2.5mg and a […]

Story Stock

Posted by Administrator on February 2nd, 2006 — in Clarinex News

42.97 -0.71: With a fourth quarter profit of $0.47 per share, Kellogg checked in a penny ahead of Wall Street’s expectations. Compared with the year-ago period, EPS rose about 4.4%. Excluding the effect of one extra shipping week in 2005, the company noted that Q4 EPS grew approximately 16%.
The company’s […]